Table 2.
Therapeutic clinical trials for COVID-19 and COVID-19-associated ARDS
| NCT number | title | status | Condition or disease | Intervention/treatment | Phase | Sponsor |
|---|---|---|---|---|---|---|
| NCT04292730 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | Completed | COVID-19 |
Drug: Remdesivir Drug: Standard of Care |
3 | Gilead Sciences |
| NCT04610541 | REMdesivir-HU Clinical Study and Severe Covid-19 Patients | Active, not recruiting | COVID-19 | Drug: Remdesivir-HU | 3 | University of Pecs |
| NCT04600999 | Clinical Trial of Favipiravir Treatment of Patients With COVID-19 | Recruiting | COVID-19 | Drug: Favipiravir | 3 | University of Pecs |
| NCT04276688 | Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | Completed | COVID-19 |
Drug: Lopinavir/ritonavir Drug: Ribavirin Drug: Interferon Beta-1B |
2 | The University of Hong Kong |
| NCT04476992 | Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement (NICOR) | Active, not recruiting |
Hypoxemia Pneumonia, COVID-19 |
Drug: Nitric Oxide-Sessions Drug: Nitric Oxide-Continuous and Sessions |
1 2 |
Federal State Budgetary Scientific Institution, Research Institute of Cardiology |
| NCT04306393 | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 (NOSARSCOVID) | Active, not recruiting | COVID-19 | Drug: Nitric Oxide Gas | 2 | Massachusetts General Hospital |
| NCT04478071 | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Recruiting |
Covid19 ARDS |
Drug: vadadustat Drug: placebo |
2 | The University of Texas Health Science Center, Houston |
| NCT04653831 | Treatment With Pirfenidone for COVID-19 Related Severe ARDS | Recruiting |
Covid19 ARDS |
Drug: Pirfenidone Other: Standard of care |
N/A | Soroka University Medical Center |
| NCT04356833 | Nebulised Rt-PA for ARDS Due to COVID-19 (PACA) | Recruiting |
Covid19 ARDS |
Drug: nebulised (rt-PA) | 2 | University College, London |
| NCT04453371 | Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) (AtTAC) | Withdrawn |
Covid19 ARDS |
Drug: Tissue plasminogen activator Drug: Ringer solution |
3 | Negovsky Reanimatology Research Institute |
| NCT04357730 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | Active, not recruiting |
Covid19 ARDS |
Drug: Alteplase 50 MG [Activase] | 2 | Denver Health and Hospital Authority |
| NCT04530578 |
Severe Acute Respiratory Syndrome Respiratory Failure Acute Respiratory Distress Syndrome |
Recruiting |
Covid19 Pneumonia |
Drug: Heparin sodium Drug: Enoxaparin |
4 | Clinica San Camilo, Argentina |
| NCT04350580 | Polyvalent Immunoglobulin in COVID-19 Related ARds (ICAR) | Completed |
Covid19 ARDS |
Drug: Human immunoglobulin Drug: Placebo |
3 | Centre Hospitalier St Anne |
| NCT04261426 | The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia | Not yet recruiting | Covid19 |
Drug: Intravenous Immunoglobulin Other: Standard care |
2 3 |
Peking Union Medical College Hospital |
| NCT04380935 | Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome | Recruiting |
Covid19 ARDS |
Biological: Convalescent plasma Drug: Standard of care |
2 3 |
Indonesia University |
| NCT04382755 | Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure (ZILU-COV) | Active, not recruiting | COVID-19 |
Drug: Zilucoplan® Drug: Placebo |
2 | University Hospital, Ghent |
| NCT04320277 | Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) | Not yet recruiting | Pharmacological Action | Drug: Baricitinib |
2 3 |
Hospital of Prato |
| NCT04359290 | Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil) | Active, not recruiting |
Covid19 ARDS |
Drug: Ruxolitinib administration | 2 | Philipps University Marburg Medical Center |
| NCT04322773 | Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (TOCIVID) | terminated (The study has been terminated due to changed clinical conditions and too few patients available) | Covid19 |
Drug: RoActemra iv Drug: RoActemra sc Drug: Kevzara sc Other: Standard medical care |
2 | Marius Henriksen |
| NCT04320615 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) | Completed | COVID-19 Pneumonia |
Drug: Tocilizumab (TCZ) Drug: Placebo |
3 | Hoffmann-La Roche |
| NCT04466098 | Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) | Active, not recruiting |
Covid19 ARDS |
Biological: Mesenchymal stromal cells Other: Placebo |
2 | Masonic Cancer Center, University of Minnesota |
| NCT04416139 | Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19) | Recruiting |
Covid19 ARDS |
Biological: Infusion IV of Mesenchymal Stem cells | 2 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| NCT04327401 | COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III (CoDEX) | Terminated (The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial results, which was accepted by the CoDEX Steering Committee.) |
Covid19 ARDS |
Drug: Dexamethasone | 3 | Hospital Sirio-Libanes |
| NCT04244591 | Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure | Completed | Covid19 |
Drug: methylprednisolone therapy Other: Standard care |
2 3 |
Peking Union Medical College Hospital |
| NCT04337190 | Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2) | Recruiting |
Covid19 ARDS |
Biological: blood sampling | – | University Hospital, Angers |
| NCT04328012 | COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED) | Recruiting | Covid19 |
Drug: lopinavir/ritonavir Drug: Losartan Drug: Placebos |
2 3 |
Bassett Healthcare |
| NCT04321096 | The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19) | Recruiting | Covid19 |
Drug: Camostat Mesilate Drug: Placebo oral tablet |
1 2 |
University of Aarhus |
| NCT04328493 | The Vietnam Chloroquine Treatment on COVID-19 (VICO) | Completed | Covid19 | Drug: Chloroquine phosphate | 2 | Oxford University Clinical Research Unit, Vietnam |
| NCT04475991 | Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults (COMVIVIR) | Not yet recruiting | Covid19 |
Drug: Maraviroc + Currently used therapy Procedure: Curently used therapy for COVID-19 non-critical patients Drug: Favipiravir + Currently used therapy Drug: Maraviroc+Favipiravir+CT |
2 | Hospital General de México Dr. Eduardo Liceaga |
| NCT04307693 | Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) | Terminated (Terminated early because no patients were further enrolled since mid-Apr 2020.) | Covid19 |
Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine sulfate |
2 | Asan Medical Center |